Systemic Bio's Innovative Breakthrough in Drug Development
A Groundbreaking Achievement for Systemic Bio
HOUSTON — Systemic Bio™, a 3D Systems company (NYSE: DDD), has been awarded the esteemed SLAS 2025 Innovation Award, celebrating groundbreaking innovations in laboratory science and automation. This accolade highlights the exceptional advancements that Systemic Bio has achieved, particularly with their unique approach to drug discovery.
The Power of h-VIOS™ Technology
At the heart of this recognition is Systemic Bio's proprietary h-VIOS™ platform, ingeniously crafted to enhance the process of drug discovery and development through the utilization of bioprinted human tissues. By focusing on the application of this innovative technology to assess the safety of antibody-drug conjugates (ADCs), Systemic Bio is reshaping the landscape of pharmaceutical testing.
Identifying Risks Early On
This cutting-edge technology stands out as it can detect safety concerns much earlier in the development process, uncovering risks that traditional methods often miss, even after non-human primate studies. By prioritizing patient safety and accelerating drug testing timelines, Systemic Bio is paving the way for a new era in pharmaceutical development.
A Testament to Dedication and Innovation
“I couldn’t be prouder of our team for winning this award,” commented Taci Pereira, CEO of Systemic Bio. This sentiment echoes the company’s commitment to showcasing the scientific and translational value of their platform. Systemic Bio remains steadfast in its mission to expand capabilities and promote the wide adoption of technologies that enhance drug discovery and development.
Production Capabilities in Houston
Located in Houston, Systemic Bio operates under rigorous conditions, housed within an ISO 7 clean room and adhering to a stringent Quality Management System (QMS). These high standards enable the production of thousands of tissue models that support ongoing collaborations with top pharmaceutical companies, focusing on improving preclinical drug testing processes and diminishing late-stage failures.
The Importance of Innovation Awards
The SLAS Innovation Award is a hallmark of technological excellence in laboratory science, awarded at the annual SLAS International Conference and Exhibition. Such recognition not only serves as a validation of Systemic Bio’s innovative contributions but also illustrates the company’s potential to lead advancements in the pharmaceutical sector.
About Systemic Bio and Its Mission
Founded in 2022, Systemic Bio is dedicated to transforming drug discovery and development with its wealth of human-relevant data derived from advanced bioprinted models. The company employs state-of-the-art bioprinting technology from 3D Systems to create precise tissue replicas using a variety of biomaterials and human cells.
Large-Scale Manufacturing and Machine Learning Integration
The unique organs-on-chips that Systemic Bio produces are not only scalable but are also crucial for studying the effects of drugs on both healthy and diseased tissues at earlier stages than ever before. With the ability to generate large datasets, this technology integrates machine learning, offering invaluable insights that are directly relevant to human therapies.
A Bright Future Ahead
This recent accolade and the continued innovation at Systemic Bio signal a forward-looking trajectory in drug development. With each step, the company is contributing to a future where drug testing is more effective and efficiently designed to address the critical needs of patients.
Frequently Asked Questions
What is the SLAS 2025 Innovation Award?
The SLAS 2025 Innovation Award recognizes exceptional advancements in laboratory science and automation, awarded annually at the SLAS International Conference.
What is Systemic Bio's primary focus?
Systemic Bio focuses on accelerating drug discovery and development through its h-VIOS™ platform, utilizing bioprinted human tissues to enhance testing accuracy.
How does the h-VIOS™ platform improve drug safety?
The h-VIOS™ platform identifies safety risks earlier in the drug development process, helping to avoid potential failures in later clinical trials.
Where is Systemic Bio located?
Systemic Bio operates from Houston, Texas, in an ISO 7 clean room, ensuring high standards in their production capabilities.
What is the significance of bioprinted human tissues in drug discovery?
Bioprinted human tissues provide a more accurate representation of human biological responses, enabling better predictions of drug effects and safety in clinical trials.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
